5 completed, 2 terminated, 1 unknown. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 5, Terminated 2, Unknown 1 |
Follow Carbidopa: new trials by email Literature Review of Carbidopa trials Research Report on Carbidopa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease Stalevo, Carbidopa and Levodopa Controlled Release Tablets - Parkinson Disease | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 180 | 2022-01-01 | 2023-02-16 |
| Vigor and the LDR in Parkinson Disease carbidopa/levodopa, as prescribed by treating physician - Parkinson Disease | Phase 4 | Completed | University of Michigan | 19 | 2020-02-12 | 2025-07-18 |
| L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults L-DOPA, Placebo Oral Tablet - Major Depressive Disorder, Dysthymia | Phase 4 | Terminated | New York State Psychiatric Institute | 51 | 2019-01-09 | 2023-05-22 |
| Norepinephrine-targeted Therapy for Action Control in Parkinson Disease Droxidopa, Carbidopa - Parkinson Disease | Phase 4 | Completed | Vanderbilt University Medical Center | 15 | 2017-04-18 | 2020-01-27 |
| Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) APOKYN, L-dopa, Trimethobenzamide - Parkinson's Disease, Motor Symptoms | Phase 4 | Completed | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | 127 | 2012-12-01 | 2023-08-14 |
| Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Levodopa/Carbidopa(200mg/50mg), Dopaminergic Agonists - Impulse Control Disorder | Phase 4 | Completed | Sandoz | 150 | 2012-11-01 | 2021-03-10 |
| Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact Levodopa-carbidopa intestinal gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, percutaneous endoscopic gastrostomy tube (PEG tube) - Advanced Idiopathic Parkinson's Disease | Phase 4 | Completed | AbbVie (prior sponsor, Abbott) | 77 | 2006-03-01 | 2016-07-18 |
| Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease. cabergoline, controlled-release levodopa / carbidopa - Parkinson Disease | Phase 4 | Terminated | Pfizer | 220 | 2004-07-01 | 2007-05-25 |
Parkinson Disease (5) · Depression (1) · Depressive Disorder, Major (1) · Disruptive, Impulse Control, and Conduct Disorders (1) · Dysthymic Disorder (1)
AbbVie (prior sponsor, Abbott) (1) · MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals (1) · New York State Psychiatric Institute (1) · Pfizer (1) · Sandoz (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · University of Michigan (1) · Vanderbilt University Medical Center (1)
United States (4) · Australia (1) · China (1) · Italy (1) · South Korea (1) · Spain (1)
Bret Rutherford, MD (1) · Gianpiera H. Ceresoli-Borroni, PhD (1) · Jinwhan Cho, MD (1) · Katherine McDonell, MD (1) · Lars Bergmann, MD (1) · Roger Albin (1)
2005 (1), R21NS114749 (1), R33MH110029 (1)